# Diabetes Hub Monitor Report — 2026-07-16

**Run type:** Automated scheduled monitor (review only — no files modified)
**Prior monitor report:** 2026-07-15
**Data freshness:** Clinical trials + PubMed refreshed today (02:05–02:06). Gap analysis last run 2026-07-15 03:14.

---

## Bottom line (what's actionable)

Quiet day. No breaking FDA action, no new Phase 3 readouts landing in our data. Two things worth a glance:

1. **Three AstraZeneca T2D Phase 3 trials flipped NOT_YET_RECRUITING → RECRUITING** (elecoglipron ± dapagliflozin program). This is the only trial-status movement since yesterday and fits our Clinical Trial Intelligence tier.
2. **54 new PubMed papers** entered the 30-day window, including a high-value 3-way cross-domain network meta-analysis comparing orforglipron / retatrutide / CagriSema. Worth reading if we're maintaining the incretin comparison synthesis.

Nothing requires urgent action. Gap analysis is 1 day old (fresh). No scripts need re-running.

---

## File System Status

All expected input files present and current:

| File | Size | Modified | Status |
|------|------|----------|--------|
| clinical_trials_latest.json | 580 KB | 2026-07-16 02:05 | Fresh |
| pubmed_recent_latest.json | 119 KB | 2026-07-16 02:06 | Fresh |
| literature_gap_data.json | 127 KB | 2026-07-15 02:15 | Current |
| literature_gap_report.md | 11 KB | 2026-07-15 03:14 | Current |
| hub_monitor_report.md | 3.8 KB | 2026-07-16 02:10 | Fresh |

hub_monitor.py reports 1,052 files tracked: 4 new, 27 modified, 0 removed since its prior scan. The 27 modifications are the daily snapshot/dashboard regeneration cycle — routine, nothing anomalous.

**Stale flag (informational):** hub_monitor flags 824 result files >14 days old. These are overwhelmingly dated daily snapshots (`clinical_trials_snapshot_*`, `agent_state.json.bak_*`) that are expected to age. No action needed, but the snapshot archive is growing (~120 files); consider a retention/prune policy if disk becomes a concern.

**Note:** hub_monitor_report.md records the hub root as `/sessions/jolly-clever-cray/mnt/...` while this run mounts under a different session ID. Same OneDrive folder, different sandbox session — not a problem, just noting the path drift.

---

## Clinical Trial Changes (858 trials tracked)

Category counts: T1D Cure & Cell Therapy 152 · T1D Immunotherapy & Prevention 76 · T2D Novel Therapies 147 · Diabetes Technology 237 · Recently Completed w/ Results 320.

### Status changes since 2026-07-15 snapshot
Only three, all the same AstraZeneca program moving into active recruitment:

- **NCT07662044** — elecoglipron alone or + dapagliflozin vs placebo, T2D (Phase 3) → **now RECRUITING**
- **NCT07662109** — elecoglipron + dapagliflozin combination, T2D (Phase 3) → **now RECRUITING**
- **NCT07662135** — (AstraZeneca T2D Phase 3) → **now RECRUITING**

[Likely] This is an oral small-molecule GLP-1 (elecoglipron) entering pivotal T2D testing — a competitor to Lilly's orforglipron in the oral-incretin race. Relevant to our Clinical Trial Intelligence tier and any incretin combination-mapping work.

### New trial added to corpus
- **NCT05574699** (Johns Hopkins) — COMPLETED, social-risk screening + closed-loop referral tool. Health-equity/implementation, not a therapeutic. Results posted 2026-07-15.

### Key Phase 3 trials — current status (key orgs)
- **Vertex zimislecel (VX-880):** NCT04786262 and NCT06832410 (kidney-transplant cohort) both **RECRUITING** Phase 3. No status change.
- **Eli Lilly baricitinib in T1D:** NCT07222137 (delay Stage 3) and NCT07222332 (BARICADE-PRESERVE, preserve beta-cell function) both **RECRUITING** Phase 3.
- **Lilly retatrutide:** multiple Phase 3 (NCT05929079, NCT06260722, NCT06297603) **ACTIVE_NOT_RECRUITING** — readouts pending.
- **Lilly orforglipron:** Phase 3 program mix of ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING.
- **Novo CagriSema:** NCT06534411 Phase 3 **ACTIVE_NOT_RECRUITING**.
- **Sanofi teplizumab:** NCT07088068 Phase 3 in Stage 3 T1D **RECRUITING**.
- **Sana Biotechnology:** no trials currently in the tracked corpus (hypoimmune islet work still early-stage / not registered under tracked queries).

### Recently posted results (last 7 days)
- **NCT05254002 (Bayer)** — finerenone + empagliflozin combo vs monotherapy in CKD + T2D. Results posted 2026-07-13. [Likely] worth a look for complication-management synthesis.
- **NCT03263494 (Jaeb)** — CGM in teens/young adults with T1D. Results posted 2026-07-09.
- Two additional (breast-cancer-survivor metabolic, social-risk referral) — tangential.

---

## PubMed Highlights (157 papers in 30-day window; +54 new since yesterday)

### Cross-domain papers (highest priority — 15 total, key ones)
- **PMID 42419792** — Network meta-analysis comparing orforglipron + retatrutide + CagriSema (3-way therapy overlap). Directly supports incretin comparative synthesis.
- **PMID 42439827** — Stem-cell-derived islets + emerging platforms to understand diabetes (T1D Cure × Multi-Omics).
- **PMID 42411999** — T1D driven by residual recipient T cells post-HCT (T1D Cure × Immunotherapy).
- **PMID 42452673** — ML framework integrating multi-omics for personalized chronic disease (AI/ML × Multi-Omics — aligns with Tier 1 #1).
- **PMID 42420766** — Early worsening of diabetic retinopathy after starting closed-loop/AID (Closed Loop × Complications). Clinically notable signal.
- **PMID 42453334** — Noncoding RNAs for diabetes therapy (Biomarker × LADA).

### Key-therapy mentions (30-day)
dapagliflozin 53 · orforglipron 10 · CagriSema 6 · retatrutide 5 · teplizumab 4 · icodec 3 · baricitinib 2 · **zimislecel 0**. Zimislecel remains publication-silent — expected; next signal will likely be a Phase 3 enrollment or interim update, not a paper.

### Volume trends
Highest 30-day raw activity: AI/ML (254), Microbiome (185), T2D GLP-1 New (171), Biomarker (165). Lowest: GLP-1 Pharmacogenomics (1), Epigenetics (5), Drug Repurposing (8), LADA (12). The thin domains (LADA, Drug Repurposing, Pharmacogenomics) continue to line up with our identified gaps below — low ambient activity, which is the opportunity.

---

## Gap Analysis Summary (BRONZE — single analytical source, expert confirmation pending)

Top 5 "potentially meaningful" intersections (Gap Score 100, near-zero joint pubs):

1. **Beta Cell Regen × Health Equity** — no equity analysis of who accesses emerging cell therapies.
2. **Insulin Resistance × Islet Transplant** — IR in graft recipients affects survival; barely studied (1 pub).
3. **Islet Transplant × Drug Repurposing** — computational screening for islet-protective repurposed immunosuppressants unexplored.
4. **Islet Transplant × Health Equity** — access-equity research absent.
5. **Gene Therapy × LADA** — no crossover despite LADA's autoimmune mechanism.

### Alignment with our Tier 1 contribution areas
- **#3 (Islet Transplant × Drug Repurposing)** maps to **Tier 1 #4 Drug Repurposing Computational Screening** — we have the tooling (OpenTargets, STRING, DrugBank) to act on this directly. Strongest actionable overlap.
- **Drug Repurposing × LADA** and **Glucokinase × Drug Repurposing** (ranks 8, 13) also sit in Tier 1 #4.
- **Metabolomics/Multi-Omics × LADA** (unclassified gaps) map to **Tier 1 #1 Multi-Omics Biomarker Integration**.

These are the gaps where we have both data access and method advantage — candidates for a computational contribution rather than just cataloguing.

---

## Breaking News (web check, last 7 days)

Nothing genuinely new since the last run:

- **Retatrutide** — 4 Phase 3 readouts through mid-2026 (TRIUMPH-1 ~28.3%, TRIUMPH-4 ~28.7% weight loss; TRANSCEND-T2D-1 in T2D). Not FDA-approved yet. Already in our trial corpus.
- **Zimislecel (Vertex)** — still investigational; FDA submission timeline accelerated to 2026, realistic approval 2027–2028. No new regulatory action this week.
- **Tzield (teplizumab)** — earlier-2026 label expansions (Stage 2, pediatric down to age 1) already reflected; no new action.
- **Orforglipron** — presented at ADA 2026; not yet FDA-approved for T2D.

No Phase 3 surprise readouts, no FDA approvals, no retractions in the window.

---

## Recommended Actions

1. **Read the incretin network meta-analysis (PMID 42419792)** — directly feeds any orforglipron/retatrutide/CagriSema comparison we maintain.
2. **Log the AstraZeneca elecoglipron Phase 3 trio** (NCT07662044/109/135) into the tracker as newly recruiting — oral-incretin competitive landscape.
3. **Review Bayer finerenone + empagliflozin results (NCT05254002)** for the complications/DKD synthesis.
4. **Consider a scoped computational pass on Islet Transplant × Drug Repurposing** (gap rank 3) — it's the highest-value gap that lands squarely in Tier 1 #4 and we have the data pipelines.
5. **No script re-runs needed.** All feeds are ≤1 day old. Optional housekeeping: prune aged `agent_state.json.bak_*` / snapshot files if the 824-stale-file count becomes noise.

---
*Generated by automated Diabetes Hub Monitor — 2026-07-16. Review run only; no source files were modified. New claims labeled with evidence levels per Research Doctrine (gap classifications remain BRONZE pending expert validation).*
